Novel therapies for chronic myelogenous leukemia

The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenou s leukemia, and immune mechanisms play an important role in control of this disease. Understanding of the molecular pathogenesis of chronic myelogenou s leukemia has led to the development of several novel therapies, which can be broadly divided into therapies based on 1) inhibition of the BCR-ABL on cogene expression, 2) inhibition of other genes important to the pathogenes is of chronic myelogenous leukemia, 3) inhibition of BCR-ABL protein functi on, and 4) immunomodulation, We have systematically review-ed each of these novel therapeutic approaches in this article. (C) 2001 International Socie ty for Experimental Hematology, Published by Elsevier Science Inc.